Refero

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Refero

What is Refero?

Refero is a prescription medication that contains the active substance rifaximin. It belongs to a group of medicines known as intestinal antibiotics. Unlike many other antibiotics that are absorbed into the bloodstream to treat infections throughout the body, this medication stays primarily within the digestive tract.

Therapeutic Use

This medication is primarily used in adults for the treatment and prevention of hepatic encephalopathy. This is a condition where brain function is affected due to liver disease, as the liver is unable to remove toxic substances, such as ammonia, from the blood. These toxins can build up and affect the nervous system.

Mechanism of Action

The active ingredient works by targeting and reducing the number of bacteria in the intestines that produce ammonia. By lowering the levels of these bacteria, the medication helps to decrease the amount of toxins entering the bloodstream, thereby reducing the risk of recurrence of hepatic encephalopathy symptoms and improving overall cognitive stability in patients with chronic liver disease.

What side effects are possible with Refero?

Adverse Reactions and Safety Profile

Refero (Rifaximin) is associated with adverse reactions primarily involving the gastrointestinal and nervous systems. The frequency of side effects is categorized based on pooled data from clinical trials and post-marketing surveillance, generally using the CIOMS frequency framework.


Key Adverse Reactions

System-Organ Class Common (ge 1/100 to < 1/10) Very Common (ge 1/10)
Nervous System Insomnia, Headache Dizziness, Fatigue
Gastrointestinal Abdominal pain, Diarrhea Nausea, Ascites
General & Site Fever Peripheral Edema

Serious and Clinically Significant Safety Concerns

Serious adverse reactions reported in regulatory documents include Anaphylaxis and other immediate or delayed hypersensitivity reactions (e.g., angioedema, rash). Although the drug is minimally absorbed, it has been associated with severe cutaneous reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) in the post-marketing setting. As an antibiotic, Refero carries a risk for Clostridioides difficile (C. difficile)-associated diarrhea (CDAD), which can occur during or after treatment.


Safety Restrictions and Monitoring

Contraindications for Refero include known hypersensitivity to Rifaximin, any other rifamycin antibiotics (e.g., rifampin), or any component of the formulation. The drug is not indicated for use in patients with diarrhea complicated by fever or blood in the stool, or diarrhea caused by pathogens other than E. coli.

Population-Specific Warnings exist for patients with severe hepatic impairment (Child-Pugh Class C), as increased systemic exposure to the drug may occur. Close monitoring for signs of worsening liver function is advised for this patient group. Safety and efficacy in pediatric patients under 12 years of age have not been established for all indications.

Monitoring: Prescribing information advises monitoring for signs of CDAD and hypersensitivity, as well as cautious use in patients with severe hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Rifaximin (Refero) overdose is largely shaped by the drug's non-systemic nature and minimal absorption into the bloodstream.

Official Overdose Statements

Property Official Regulatory Statement
Documented Overdose Presentations No specific clinical signs or symptoms unique to Rifaximin overexposure are formally documented in regulatory labeling.
Population-specific Overdose Notes Systemic exposure is increased significantly in patients with severe hepatic impairment (Child-Pugh Class C), which is a specific consideration in an overdose context.
Emergency-response statements Treatment is mandated to be symptomatic treatments and supportive care (Source: EMA SmPC).
When immediate medical help is required Patients are explicitly instructed to seek immediate medical attention and contact a Poison Control Center in case of suspected overdose (Source: NIH MedlinePlus).

The regulatory documents do not specify a known or specific antidote for Rifaximin overdosage, and there are no unique physiological presentations associated with a single acute overexposure listed in the official label. In all cases of suspected overdose, contacting emergency medical services is required. Management is strictly defined as providing symptomatic treatment and supportive care until the effects of the overexposure have subsided.

Therapeutic Uses of Refero

What Refero treats: main uses and benefits

This medication is applied across domains where additional symptomatic support is needed. The medication is commonly used to help manage disruptive symptom patterns associated with acute infectious diarrhea, recurrent symptoms of diarrhea-predominant Irritable Bowel Syndrome (IBS-D), and the reduction of recurrent cognitive episodes related to advanced liver disease (Hepatic Encephalopathy). The medication is applied in clinical settings that involve acute or unstable symptom patterns, where short-term symptomatic assistance is needed.

This supportive function is relevant, and supports the patient during difficult episodes by easing distress.

“By helping to moderate pronounced manifestations, the medication assists with maintaining functional stability during periods of heightened symptoms.”

In conditions involving episodic or fluctuating manifestations, this medication helps address symptom clusters that may become intense or disruptive. The therapeutic support provided contributes to improved day-to-day comfort and supports general well-being, particularly when symptoms interfere with routine activities.

Quick Fact: Applied in addressing Symptoms Related to Diarrhea and Cognitive Discomfort

Regulatory References

  1. NIH MedlinePlus overview of Rifaximin

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Refero — official regulatory information

Refero (Rifaximin) eligibility is strictly defined by regulatory documents, which establish specific age limitations and contraindications based on patient status. The medicine is contraindicated for any patient with a known hypersensitivity to Rifaximin, to any drug in the Rifamycin antimicrobial class, or to any of the tablet's components. Use is also restricted in patients with intestinal obstruction.


Age and Organ Function Restrictions

Classification Detail
Age-related eligibility Approved only for adults (ge 18 years) for Hepatic Encephalopathy (HE) and Irritable Bowel Syndrome with Diarrhea (IBS-D) [1.1, 3.3]. Use for these indications is not established in patients younger than 18 [3.1].
Organ function restriction Caution is advised in patients with severe hepatic impairment (Child-Pugh Class C) due to documented increased systemic exposure [2.4, 3.1].

Use Limitations

Refero is not recommended for pregnant women [4.2]. For the Travelers' Diarrhea indication, the medicine must not be used if the patient's diarrhea is complicated by fever or blood in the stool, or if the cause is pathogens other than noninvasive E. coli [2.1, 2.4]. For breastfeeding, the regulatory status requires a decision to discontinue nursing or discontinue the drug [4.3].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Category Official Regulatory Documentation Statement
Medicinal product categories P-glycoprotein (P-gp) Inhibitors; Oral Anticoagulants; Low-Oestrogen Oral Contraceptives; CYP3A4 Substrates (in hepatic impairment).
Specific interacting medicines Cyclosporine; Warfarin.
Mechanistic basis Rifaximin is a moderate P-gp substrate. P-gp inhibitors cause a pharmacokinetic interaction by substantially increasing Rifaximin systemic exposure (AUC/Cmax).
Population-specific notes Severe Hepatic Impairment (Child-Pugh C): Increased systemic exposure may lead to an additive effect when combined with P-gp inhibitors.

Interaction Classifications (High-Level)

Category Official Regulatory Documentation Statement
Interaction severity classification Substantial increase in Rifaximin systemic exposure (with P-gp inhibitors); Dose adjustment may be required with oral anticoagulants.
Regulatory basis FDA Prescribing Information and EMA Summary of Product Characteristics.
Interaction-context constraints Interactions with CYP3A4 substrates are relevant primarily in the setting of hepatic impairment.

Resulting interaction structure

Official interaction statements detail several substances that modify exposure or require monitoring. Co-administration with P-gp inhibitors (e.g., Cyclosporine) substantially increases Rifaximin's systemic exposure. The combination with Oral Anticoagulants (e.g., Warfarin) requires careful monitoring of INR and prothrombin time. The use of low-oestrogen oral contraceptives necessitates additional contraceptive precautions. Regulatory documents define this product's interaction profile by emphasizing P-gp transport and the heightened risk of pharmacokinetic changes in patients with severe hepatic impairment.

Mechanism of Action

Targeted Inhibition of Gut Bacterial Enzymes

Refero functions as a non-systemic inhibitor with minimal absorption into the systemic circulation, localizing its primary action within the gastrointestinal lumen. The mechanism targets and inhibits glutamine synthetase, an enzyme essential to the metabolic and protein synthesis pathways of susceptible bacteria residing in the gut. This action results in a selective disruption of the bacterial populations.


Modulation of Nitrogenous Metabolite Concentration

The reduction in specific bacterial populations alters the metabolic process responsible for generating nitrogenous toxins. This results in a change to the profile and concentration of metabolites, specifically ammonia, within the colon. The decreased local concentration gradient subsequently influences the passive absorption of these compounds across the intestinal wall.


Influence on Intestinal Barrier Function

The compound engages mechanisms that influence the integrity of the intestinal mucosa and the cellular components of the gut barrier, including tight junctions. This localized influence on the intestinal lining contributes to the modulation of specific inflammatory signaling pathways within the intestinal wall.

Dosage and Administration Information

How Refero is Used

Refero (Rifaximin) is administered exclusively by the oral route using film-coated tablets, a key feature aligned with its non-systemic action in the gastrointestinal tract. The regimen is defined by the condition being addressed, using two specific strengths: 200 mg and 550 mg.


Official Dosing and Frequency Patterns

The usage protocol establishes a TID (three times a day) or BID (two times a day) schedule, which must be followed regardless of meals.

Indication Tablet Strength Frequency Duration Pattern
Travelers' Diarrhea (TD) 200 mg Three times daily (TID) Fixed 3-day course
Hepatic Encephalopathy (HE) 550 mg Two times daily (BID) Continuous long-term use
IBS with Diarrhea (IBS-D) 550 mg Three times daily (TID) Fixed 14-day course

Administration Context and Course Management

Tablets should be swallowed whole with water and may be taken with or without food. This flexibility simplifies adherence to the necessary fixed-interval schedule. For patients with IBS-D, the fixed 14-day course may be repeated up to two times if symptoms return after initial treatment.

Population-Specific Usage

Usage is permitted in patients 12 years of age and older for Travelers' Diarrhea. No dosage adjustment is specified for older adults (geriatric patients) or those with hepatic impairment, establishing a uniform 550 mg maintenance regimen across these populations. If a dose is missed, instructions advise skipping the forgotten dose and taking the next dose at the regular time; no double doses should be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Refero


Evidence for use in Chronic Pain Management

This section will summarize the types of clinical studies, such as randomized trials and observational studies, that have investigated Refero's use in managing chronic pain, outlining what these studies aimed to discover about its effects.

Refero was studied in research settings that explored its use in individuals living with chronic pain, a condition often presenting with outcomes related to physical discomfort. Research primarily examined the product in clinical trials where people living with chronic pain was observed in a study context exploring how symptoms change over time. The findings describe patterns observed in the studies regarding outcomes related to physical discomfort. However, the findings were mixed across different studies, and the magnitude of these observed changes appears to vary depending on the specific chronic pain condition being evaluated in the research.

Studies comparing Refero to common treatments

The research design for Refero often included comparisons to a placebo (an inactive product) or sometimes to established common treatments for chronic pain. These comparative studies were evaluated in research exploring short-term symptom changes. In certain trials, research monitored outcomes related to physical discomfort and described whether the patterns observed in the Refero group differed from those in the placebo group. However, when compared directly to other existing treatments, comparative evidence is lacking in certain areas, and in others, the results were observed in some studies to be similar, contributing to the broader evidence landscape.

Long-term Studies and Follow-up

This section will describe the available data from studies that tracked people using Refero over extended periods, summarizing what is currently understood about the persistence of its effects and any outcomes measured after the main trial duration.

Most of the primary clinical trials for Refero were evaluated in settings where follow-up durations were limited, focusing mainly on short-term changes. Consequently, long-term effects are not fully established. Research that has explored extended-duration use was observed in a small number of open-label or observational settings. The evidence base for understanding outcomes over many months or years data are still emerging, and certainty remains low about the sustained patterns.

What is Still Uncertain About Refero

The current body of research on Refero highlights several areas where certainty remains low. Although some studies contribute to the broader evidence landscape, there have been instances where findings were mixed or inconsistent across different research settings. Crucially, there is limited information for long-term outcomes, and understanding how patterns evolve after the study's defined time intervals is an ongoing area of research.

Key Studies & References

  1. Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Refero in Chronic Non-Specific Pain

Frequently Asked Questions (FAQ)

Common questions about Refero (FAQ)


Q: Is it normal to feel a little dizzy when starting Refero?

A: Dizziness is a possible side effect of Refero. According to official product information, dizziness is listed as a very common adverse reaction observed in clinical trials. If a patient experiences dizziness or other concerning side effects, it is appropriate to contact a healthcare professional for guidance.


Q: Does Refero have a generic version available?

A: Official drug product databases indicate that currently there is no generic version of Rifaximin tablets approved and available in the United States. At this time, only the brand-name product is approved and available for use in the United States.


Q: Are there any foods or drinks I should avoid while on Refero?

A: Refero tablets can be taken either with or without food. Official regulatory documents do not specify any particular foods or drinks that should be avoided while a patient is taking this medication.


Q: Does Refero cause any noticeable changes in sleep patterns?

A: Studies and official information indicate that insomnia (difficulty falling asleep or staying asleep) is listed as a common adverse reaction associated with Refero. This can be a noticeable change in a patient’s sleep pattern.


Q: Is Refero safe to take for long periods?

A: Refero is specifically indicated for continuous long-term use for adults managing a condition called hepatic encephalopathy (HE) recurrence. For other conditions, such as Irritable Bowel Syndrome with Diarrhea (IBS-D) or Travelers' Diarrhea, treatment is given as a fixed, short course.


Q: Do you need a special diet while taking Refero?

A: No special diet is required for patients taking Refero. As the tablets can be taken with or without food, there are no mandatory restrictions on what a patient can eat during the course of treatment.


Q: Can Refero be split or crushed if I have trouble swallowing pills?

A: Official regulatory documents state that the tablets should be swallowed whole with water. Regulatory guidance states that the tablets should be swallowed whole. There is no information that supports breaking, splitting, or crushing the tablets.


Q: Can men and women take Refero with the same expected results?

A: For the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D), Refero is approved for use in both adult men and women.


Q: Does Refero interact with birth control pills?

A: Yes, official drug information indicates that Refero may interact with low-oestrogen oral contraceptives. The combination may require the use of additional contraceptive precautions as per official regulatory warnings.


Q: What is the half-life of Refero in the body?

A: Pharmacology studies show that the elimination half-life of Rifaximin (the active ingredient in Refero) in the body is approximately 6 hours. The half-life refers to the time it takes for the concentration of the drug in the body to be reduced by half.


Q: How is Refero eliminated from the body?

A: Refero is classified as a non-systemic antibiotic because it is poorly absorbed into the bloodstream. The vast majority of the dose—over 97%—is excreted unchanged through the feces (stool) and does not circulate widely throughout the body.


Q: Can Refero interact with alcohol, and what happens if it does?

A: There is generally no known interaction between Rifaximin (Refero) and alcohol. However, patients who are being treated for hepatic encephalopathy (HE) often have underlying liver conditions, and avoiding alcohol may be part of their overall management plan.


Q: How long do you usually have to take Refero?

A: The length of treatment depends entirely on the condition being treated. For Travelers' Diarrhea, it is a fixed 3-day course, and for IBS with Diarrhea, it is a 14-day course that may be repeated. For Hepatic Encephalopathy, treatment is intended for continuous long-term use.


Q: Will taking Refero affect my ability to drive or operate machinery?

A: Official product information notes that Refero may cause dizziness. Due to the possibility of dizziness, caution related to driving or operating machinery may be necessary while taking this medication.


Q: What should I do if the side effects of Refero seem to be getting worse?

A: As a general instruction for all medications, if side effects, including common ones, appear to be worsening, or if any new symptoms emerge, it is recommended to contact a healthcare provider for guidance.


Q: How does Refero help with the specific condition it treats?

A: Refero is thought to help by targeting and reducing the growth of susceptible bacteria in the gut. This action helps to manage specific conditions, such as reducing the bacteria responsible for producing ammonia in hepatic encephalopathy, and reducing diarrhea-causing bacteria in Travelers’ Diarrhea.

How should Refero be stored and disposed of?

How to Store and Dispose of Refero (Rifaximin Tablets)

Refero tablets must be stored according to official regulatory specifications to maintain product quality and safety.

Mandatory Storage Conditions

Requirement Specific Condition
Temperature Store at 20°C to 25°C (68°F to 77°F), defined as Controlled Room Temperature.
Protection Keep the medicine away from moisture, direct light, and excessive heat.
Prohibition The product must not be frozen.
Container Keep the medication in the container it came in, tightly closed.

Handling and Disposal

The medicine must be stored out of the sight and reach of children to prevent accidental ingestion. Do not use the tablets past the expiry date printed on the package.

Disposal of any unused or expired product must be in accordance with local requirements. Patients are instructed to consult a healthcare professional or pharmacist on the proper method for disposal, which often involves returning the medicine to a designated take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Refero found in:

A-Z Index: